Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation


Background

Metabolic and cardiovascular health problems have become a major focus for clinical care and research in schizophrenia.

Aims

To evaluate the content and quality of screening guidelines for cardiovascular risk in schizophrenia.

Method


Results

The AGREE domain scores varied between the 18 identified guidelines. Most guidelines scored best on the domains 'scope and purpose' and 'clarity of presentation'. The domain 'rigour of development' was problematic in most guidelines, and the domains 'stakeholder involvement' and 'editorial independence' scored the lowest. The following measurements were recommended (in order of frequency): fasting glucose, body mass index, fasting triglycerides, fasting cholesterol, waist, high-density lipoprotein/low-density lipoprotein, blood pressure and symptoms of diabetes. In terms of interventions, most guidelines recommended advice on physical activity, diet, psychoeducation of the patient, treatment of lipid abnormalities, treatment of diabetes, referral for advice and treatment, psychoeducation of the family and smoking cessation advice. Compared across all domains and content, four European guidelines could be recommended.

Conclusions

Four of the evaluated guidelines are of good quality and should guide clinicians’ screening and monitoring practices. Future guideline development could be improved by increasing its rigour and assuring user and patient involvement.

Declaration of interest

M.D.H. has been a consultant for, received grant/research support and honoraria from, and been on the speakers/ advisory boards of AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer and Sanofi Aventis. He is co-author of two of the assessed guidelines. C.C. has been a consultant to, or has received honoraria from, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Mediceure, OrthoMcNelli-Janssen, Otsuka, Pfizer, Schering-Plough, Supernus, and Vanda, and has served on the speaker’s bureau of AstraZeneca, Bristol-Myers Squibb/Otsuka and Pfizer. J.P. has been a consultant for and co-operated in clinical trials with AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, Sanofi Aventis. He has also received research grants from AstraZeneca, Janssen-Cilag, Eli Lilly, Lundbeck and Sanofi-Aventis. R.V.W. has been a consultant for Eli Lilly and received honoraria from AstraZeneca, Eli Lilly and Janssen-Cilag.

In recent years, physical health issues and specifically metabolic and cardiovascular comorbidity in different severe mental illnesses have become a major focus in both clinical care and research.1–10 The association of schizophrenia with metabolic and other cardiovascular disease risk factors is a complex interplay between environmental (lifestyle, diet, substance use), genetic and illness-related factors, such as specific symptoms, as well as effects of treatment. Both older and more recent studies have confirmed the high rate of premature mortality in people with schizophrenia due to cardiovascular disease.11–20

The need for screening, monitoring and prevention of diabetes and other cardiovascular disease risk factors has been acknowledged in the psychiatric literature and in some of the more recent general treatment guidelines.21–25 However, the evaluation of screening practices by clinicians has consistently shown that they are suboptimal.26–37 Different national and international groups have developed guidelines relating to the monitoring and management of the increased risk for physical comorbidity in people with schizophrenia. A review in 2006 indicated substantial differences between six guidelines.38

Guidelines on the same topic, in different domains in medicine, can differ or be in conflict with other recommendations in the same domain.38 Not all guidelines have been developed with the same amount of rigour and authors’ independence. Clinicians should be able to identify and have access to guidelines, which are based on the best evidence. For the individual clinician as well as services it can be difficult to identify and select a specific recommendation to use in daily practice.

The aim of this study was to perform a systematic review of the available clinical practice guidelines for the screening and monitoring of cardiometabolic risk in people with schizophrenia and related psychotic disorders. The quality of these guidelines is assessed with the Appraisal of Guidelines for Research and Evaluation (AGREE).39–40

Method

Clinical practice guidelines for the screening and monitoring of people with schizophrenia were identified by a systematic search using PubMed, CINAHL and Embase (from 1 January 2000 until 1 April 2010) and the following search terms: Schizophrenia, Psychotic disorder, Psychosis, Mental illness, Diabetes, Cardiovascular diseases, Metabolic syndrome, Safety management and prevention, Guideline(s), Consensus development, Practice guideline(s). In the retrieved papers related articles were identified in reference lists.
Exclusion criteria were: papers only evaluating or comparing the effects of specific antipsychotic agents; general treatment guidelines for schizophrenia or psychotic disorders; guidelines specific for diabetes or cardiovascular diseases; guidelines only for children, adolescents or elderly people. All European languages were allowed if the papers met all of the following inclusion criteria: schizophrenia, cardiometabolic risk, adults and guidelines.

The evaluation and comparison of the guidelines was performed according to AGREE (2003), which is designed as a framework for the assessment of the quality of guidelines for clinical practice (www.agreecollaboration.org).49–50

The instrument consists of 23 items grouped in six domains: scope and purpose; rigour of development; stakeholder involvement; clarity and presentation; applicability; and editorial independence. Each item is scored on a 4-point scale (strongly agree, agree, disagree and strongly disagree) with proposed anchor points to evaluate in which way the guideline fulfils the domain. The scores are standardised in a percentage score that enables comparison between guidelines. A total of 54 guidelines were found of which 35 were included: 23 duplicate papers (either by the same or different authors with similar guideline content in different journals);52–63 4 general schizophrenia treatment guidelines;53–55 4 guidelines only for children or adolescents;56–58 2 for people with bipolar disorder;59–61 and 3 diabetes guidelines.62–64 One guideline for metabolic screening in people with schizophrenia was excluded because it was only available in Japanese and we were not able to get it translated.24

A total of 18 unique guidelines were identified for AGREE evaluation either from the USA (2), Australia (2), Brazil (1), Canada (1) or Europe (12), and all were published between 2004 and 2010 (online Table DS1).75–92 All papers covered diabetes and cardiovascular disease risk in individuals treated with antipsychotic agents, whereas some had a broader scope also including other physical health domains and other side-effects.78,85,86,89,91

**Results**

The initial search with all search terms yielded 4608 hits (Fig. 1). That number was reduced to 18 when the specific inclusion criteria were applied. A total of 54 guidelines were found of which 35 were excluded: 23 duplicate papers (either by the same or different authors with similar guideline content in different journals);52–63 4 general schizophrenia treatment guidelines;53–55 4 guidelines only for children or adolescents;56–58 2 for people with bipolar disorder;59–61 and 3 diabetes guidelines.62–64 One guideline for metabolic screening in people with schizophrenia was excluded because it was only available in Japanese and we were not able to get it translated.24

A total of 18 unique guidelines were identified for AGREE evaluation either from the USA (2), Australia (2), Brazil (1), Canada (1) or Europe (12), and all were published between 2004 and 2010 (online Table DS1).75–92 All papers covered diabetes and cardiovascular disease risk in individuals treated with antipsychotic agents, whereas some had a broader scope also including other physical health domains and other side-effects.78,85,86,89,91

**Interrater reliability**

The overall ICC value among the observers was 0.89 (95% CI 0.88–0.91, P<0.0001). None of the scores on individual items for all assessed guidelines differed more than one point on the AGREE scale.

**Evaluation of the quality of the guidelines**

There was wide variation in standardised scores of the different domains (online Table DS1). Apart from stakeholder involvement, all of the domains had a difference of at least 45% between the highest and lowest scoring guideline. Only two domains had a mean score above 50% (scope and purpose, clarity and presentation).

The highest mean domain score, derived from pooled scores, was for scope and purpose (56.4%) with five guidelines scoring below 40% and six having a score of 70% or above. The highest score, 81.5%, was achieved by three guidelines.75,77,79

Clarity and presentation was satisfactory in most guidelines (50.6%), only four had a score of 31% or lower. All the guidelines with a score above 50% presented a clear table or figure, summarising the proposed screening content and time intervals.

Regarding the domain rigour of development all except one guideline had a score below 50%.89 Although some guidelines presented data from a systematic review of the literature, the search strategy for literature selection was missing in all but one guideline.89 Only two guidelines presented levels/evidence44,66 and one presented meta-analytic data.89 More than half (61%) of the guidelines were developed with a consensus model (online Table DS2). Within this domain the criterion about the updating of the recommendation was not fulfilled by any of the guidelines. The older UK guideline has a low score on this item, but the paper was published in a themed issue of the journal, with different papers presenting a systematic review of the literature in that same issue.81

Scores in the application domain were satisfactory in five guidelines. The guidelines with a low score on this domain failed to discuss the organisational aspects of introducing screening and monitoring. Health economic aspects were mentioned in some guidelines but the additional cost of screening and monitoring was explicitly available in only one.91

---

**Fig. 1 Results of the systematic literature search.**
Editorial independence was the only domain with a range of scores from 0 to 100%. Eight guidelines had industry involvement and in only seven there was a declaration of conflicts of interest. Some publications were not industry sponsored but lacked a conflict of interest section resulting in a low AGREE score on this item (online Table DS7).

The lowest mean domain score was for stakeholder involvement (30.6%), with only six guidelines scoring above 30%. Only in two guidelines had patients been involved in the guidelines’ development. The proposed guidelines were never tested on the intended users. Except for three,76,85,92 all the guidelines were developed by a multidisciplinary group. Official medical societies were involved in the oldest75 and in six of the seven most recent guidelines (online Table DS2).78,79,82,83,89,90

Comparing the guidelines across the overall scores in the different domains, four European77,79,83,89 and one US guideline could be recommended, whereas four guidelines failed in nearly all domains.76,85,87,92

**Guideline development process**

Online Table DS2 presents details about the guideline development process. Most were based on a selective or systematic literature review. A majority was based on a consensus model involving different medical disciplines. People with schizophrenia were the target for the proposed recommendations in all guidelines, although some broadened the scope to people with other severe mental illnesses being treated with antipsychotic medication. Four guidelines specifically mentioned pediatric patients as a vulnerable group.74,78,79,85

**Recommended assessment of risk factors for diabetes and cardiovascular disease**

All but one guideline recommended assessment of family history, and three failed to include personal history (online Table DS3). Only 56% of the guidelines proposed a general physical examination of the patient. Assessment of other known risk factors for diabetes and cardiovascular disease was incomplete in most of the guidelines; 44% even failed to mention smoking. Three included a comprehensive risk assessment.79,80,91

Most of the guidelines stated that the frequency of monitoring is dependent on the presence of risk factors (including being overweight and obesity) and on the time since starting the antipsychotic medication (more frequent monitoring when close to starting medication) (online Table DS4). A minority of guidelines (28%) suggested that the frequency of monitoring is dependent on specific antipsychotic agents. In most cases, they stipulated that it is the responsibility of the psychiatrist/prescriber to ensure that the screening and monitoring is being conducted. Six guidelines explicitly also involved a general practitioner (GP) in this responsibility and promoted models of shared care.78,81,83–91

**Comparison of recommendations in the guideline**

Overall, the recommendations across guidelines were more similar than dissimilar regarding variables that should be assessed both at baseline and over time (online Table DS5). Apart from weight and body mass index, which were present in most guidelines (89%), a majority of guidelines also included measurements of waist circumference (83%). All guidelines also included the assessment of fasting glucose (online Table DS5), and the majority (89%) also included the assessment of fasting lipids (online Table DS5). The major differences between guidelines were in the timing and the interval between assessments. The more recent guidelines were more detailed and included additional evaluations about personal and family history and cardiovascular risk factors. Six guidelines (33%) failed to mention blood pressure monitoring. A substantial number of them also failed to mention specific timing for screening or to mention cut-off or target values for the assessed variables (most frequently for the lipid measurements). For glucose values the reference values presented were either based on the American Diabetes Association or World Health Organization thresholds at the time of publication. For lipid values, the cut-offs of the Adult Treatment Panel were used most frequently. In 60% of the guidelines, the reference values were based on the recommendations of official societies (either cardiology or diabetology).

For glucose abnormalities, four guidelines mentioned the possibility of assessing non-fasting glucose (although they, at the same time, recommended assessing fasting lipid profile) and only two recommended glycosylated haemoglobin (HbA1c). Oral glucose tolerance tests were recommended in six; in case of impaired fasting glucose values.77,80,82–84,88 Monitoring for signs and symptoms of diabetes was recommended by different guidelines (67%), whereas only a few (33%) explicitly mentioned assessing diabetic ketoacidosis (online Table DS6). The concept of the metabolic syndrome was formally included in only four.

Guidelines with a more global physical health scope recommended additional laboratory testing, ranging from prolactin levels to viral serology and different additional somatic investigations (online Table DS6). In total, 50% proposed ECG monitoring, at least when using drugs with a potential for QTc prolongation.

**Discussion**

This is the first study that systematically evaluates the content and quality of practice guidelines for the screening and monitoring of diabetes and cardiovascular risk in people with schizophrenia. For the qualitative and quantitative assessment of these guidelines, we used AGREE, a widely used and accepted tool for the quality assessment of such material.39,40 The assessed guidelines differed significantly regarding the different AGREE domains. The highest scores were obtained for scope and purpose and clarity of presentation. The lowest scores were found for the domains stakeholder involvement and rigour of development. There was less difference between the basic sets of variables that should be assessed in patients, but substantial differences were apparent in the level of detail and timing of the recommended monitoring and proposed therapeutic strategies.

**Clinical recommendations**

After a baseline assessment, 10 of the 18 guidelines recommended monitoring after the first 3–4 months of treatment, but 4
recommended monitoring after 4–6 weeks and 1 required only monitoring at 6 months. The following measurements were recommended, in order of frequency: fasting glucose, body mass index, fasting triglycerides, fasting cholesterol, waist, high density lipoprotein/low density lipoprotein, blood pressure and symptoms of diabetes. In terms of interventions, most guidelines recommended advice on physical activity, advice on diet, psychoeducation of the patient, treatment of lipid abnormalities, treatment of diabetes, referral for advice and treatment, psychoeducation of the family and smoking cessation advice. Of the screening tests, fasting glucose, fasting triglycerides and fasting cholesterol may be less easily integrated into routine care because of the need to organise fasting blood tests. Thus compliance with such tests is often less than 20%.\textsuperscript{28,29,3}\textsuperscript{1} Alternatives such as non-fasting HbA1c are promising but require further validation in psychiatric settings.\textsuperscript{93–95}

**Implementation of guidelines**

Clinical practice guidelines are considered a good option for translating research into clinical practice. They are defined as ‘systematically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances’.\textsuperscript{96} Their potential to improve patient care and outcomes depends largely on the quality and independence of the guideline.\textsuperscript{97} Recommendations may be biased because of non-systematic selection, inadequate interpretation or lack of scientific evidence. The content may initially be decided through consensus, whereas scientific evidence to support the consensus is added afterwards. The influence of the context within which the guidelines are produced (for example by medical societies or with support of pharmaceutical companies) has also been mentioned in relation to the variation across guidelines.\textsuperscript{97–99}

Quality evaluations have recently been performed for other diseases in relation to metabolic and cardiovascular risk monitoring.\textsuperscript{100–102} Similar to our findings, for diabetes and cardiovascular disease the rigour of development and other quality indications, such as stakeholder involvement and editorial independence, were not ideal in a number of these guidelines. This was the case, despite medical societies developing stringent methodologies for these diseases according to internal guidelines/procedures.\textsuperscript{103} Moreover, editorial independence was also often a problematic area, and frequently guidelines were not based on high-quality evidence.\textsuperscript{98–104}

**Limitations**

A limitation of the AGREE methodology is the degree of subjective judgement.\textsuperscript{100,101} This can be partly overcome through the evaluation by different independent reviewers, as was done in this study, and with high interrater reliability. We did not contact the original authors for additional information. This could have been relevant for those guidelines not having industry sponsoring, but failing to report conflicts of interest (in the appraisal, such guidelines received a score of ‘totally disagree’ on item 22). Furthermore, the AGREE evaluation does not evaluate the impact of the guidelines on patient outcome.\textsuperscript{100}

Authors of a recent joint paper on the Schizophrenia Patient Outcomes Research Team (PORT) guidelines acknowledged the difficulty of getting published guidelines to change clinical practice.\textsuperscript{105} This is supported by a number of studies. So far all studies that assessed the impact of the American Diabetes Association/American Psychiatric Association (ADA/APA) 2004 guidelines\textsuperscript{76} in the USA, which went hand in hand with extensive educational efforts, suggest that the impact on real-life screening and monitoring rates of people receiving antipsychotics in different population samples in the USA is minimal to poor.\textsuperscript{28–34} Similar results have also emerged in the UK.\textsuperscript{27} Of note, although often calling for research, none of the guidelines explicitly mentioned an update procedure. The only guideline that has undergone an extensive review and update process is the ADA/APA consensus document.\textsuperscript{77} A new version of this guideline is currently being finalised.

**General conclusions**

Overall, we conclude that several adequate guidelines for screening and monitoring are available. The published guidelines all focus on the same evidence base but differ mainly regarding the timing of monitoring and the scope of physical health domains that are to be monitored. Comparing the guidelines across the overall scores in the different domains of the AGREE assessment and taking into account the level of detail and comprehensiveness of the monitoring, four European guidelines can be recommended for clinical use in daily practice.\textsuperscript{77,79,83,89} However, none of the guidelines had a proposed schedule for an update and they all require more rigorous implementation strategies, together with studies into the impact on actual screening rates; long-term patient outcomes should also be put in place.

Based on this review of the guidelines, a monitoring protocol for managing cardiovascular disease risk in patients in clinical practice is proposed in Fig. 2. All individuals with schizophrenia should be under active care (regardless of treatment condition) and be screened at least annually if they have normal baseline values. Those who already present with cardiovascular risk factors should be monitored more frequently. At the start of a new treatment, assessments should be repeated 6 and 12 weeks after initiation of the new antipsychotic drug treatment (the 6-week assessment has only been endorsed in some European guidelines and the advantages of this additional, early assessment time point still have to be demonstrated). These recommendations are in general agreement with the National Institute for Health and

<table>
<thead>
<tr>
<th>Baseline</th>
<th>6 weeks (if starting drug treatment)</th>
<th>12 weeks (if starting drug treatment)</th>
<th>At least annually thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical history</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Weight/waist/BMI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fasting lipids</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Lifestyle advice</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Fig. 2 Monitoring protocol for managing individuals with normal baseline values at start of an episode of care.

The 6-week assessment has only been endorsed in some European guidelines and the advantages of this additional, early assessment time point still have to be demonstrated. Body mass index (BMI): during initial phases of treatment, it is important to measure weight weekly to identify individuals who may be gaining weight rapidly.
Clinical Excellence guidelines, which stress the need to prevent cardiovascular disease and to undertake metabolic risk assessment, but do not provide clear guidance on which evaluations need to be done when, and with the Canadian Diabetes Association clinical practice guidelines, which considers schizophrenia as a risk factor for diabetes. Based on a systematic review of the metabolic effects of antipsychotics in children and adolescents, similar guidelines for cardiometabolic screening have been proposed recently. Based on recent data in drug-naive individuals, and general treatment guidelines, antipsychotic medications with a high liability to induce metabolic changes are not recommended to be used as first-line agents in first-episode/never exposed individuals.

As in other healthcare domains, improvement is needed in the quality of the guidelines for screening and monitoring cardiometabolic risks in people with schizophrenia. In order for this shift to happen, guidelines should adhere more closely to the methodology proposed in the AGREE instrument. Finally, due to the increasing burden of obesity among individuals with schizophrenia and the potential for long-term cardiometabolic comorbidities, clinicians need to have access to key recommendations from the best available guidelines, be critical of how these are developed and consider their appropriateness for use in their own clinical practice.

References


12 Colton CW, Manderscheid RW. Convergences in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3: A42.

13 De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010; 117: 68–74.


